Advertisement

Digestive Diseases and Sciences

, Volume 42, Issue 4, pp 751–761 | Cite as

Systemic and Hepatic Hemodynamics in Hepatosplenic Manson's Schistosomiasis with and Without Propranolol

  • Sergio Mies
  • Oddone Braghirolli Neto
  • Andre Beer
  • Carlos E.S. Baia
  • Fernando Alfieri
  • Leila M.M.B. Pereira
  • Marcelo J.A. Sette
  • Silvano Raia
Article

Abstract

Systemic and hepatic hemodynamics wereprospectively studied in 11 patients with Manson'sschistosomiasis and portal hypertension, as well asalterations resulting from the use of propranolol. Itwas decided that patients whose portal pressure was reducedby 30% with the use of the drug would not undergosurgery and that treatment would consist of the chronicuse of propranolol, associated with sclerosis of esophageal varices. This objective was not metby any of the patients whose portal pressure wasmeasured and the study was interrupted. Results showthat patients with Manson's schistosomiasis and portal hypertension have hyperdynamic circulation,mild pulmonary hypertension, greatly increased splenicblood flow, and preservation of total hepatic bloodflow. Administration of propranolol correctshyperdynamic circulation, aggravates pulmonary hypertension,does not alter portal pressure and reduces the sectorialportal blood flows, especially of the azygos vein, withmaintenance of total hepatic blood flow. These data favor the hypothesis of portaloverflow in the physiopathology of portal hypertensionof schistosomiasis.

PORTAL HYPERTENSION MANSON'S SCHISTOSOMIASIS PROPRANOLOL HEMODYNAMICS 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Alves CAP, Alves AR, Abreu WN, Andrade ZA: Hepatic artery hypertrophy and sinusoidal hypertension in advanced schistosomiasis. Gastroenterology 72:126–128, 1977Google Scholar
  2. 2.
    Ramos OL, Saad F, Leser WP: Portal hemodynamics and liver cell function in hepatic schistosomiasis. Gastroenterology 47:241–247, 1964Google Scholar
  3. 3.
    Strauss E, Silva LC, Raia S: Fluxo sangümeo hepático. Arq Gastroenterol 13:41–50, 1976Google Scholar
  4. 4.
    Raia S, Mies S, Alfieri Jr. F: Portal hypertension in mansonic schistosomiasis. World J Surg 5:176–187, 1991Google Scholar
  5. 5.
    Andrade ZA, Cheever AW: Alterations of the intrahepatic vasculature in hepatosplenic schistosomiasis mansoni. Am J trop Med Hyg 20:425–432, 1971Google Scholar
  6. 6.
    Morgan JS, Groszmann RJ, Rojkind M, Enriquez R: Hemodynamic mechanisms of emerging portal hypertension caused by schistosomiasis in the hamster. Hepatology 11:98–104, 1990Google Scholar
  7. 7.
    Coutinho A: Altera{ie759-1}s hemodinâmicas na esquistossomose mansônica hepato-esplenica. J Bras Med 8:299–309, 1964Google Scholar
  8. 8.
    Andrade ZA, Andrade SG: Patologia da esquistossomose hepatesplènica. In Aspectos peculiares da infec{ie759-2} por Schistosoma mansoni. ES Azevedo, G Rebouças, H Rocha, LGC Lyra, RS Teixeira, S Andrade, ZA Andrade (eds). Salvador, Centro Editorial e Didático da UFBA, 1984, pp 103–131Google Scholar
  9. 9.
    Lopes de Faria J: Pulmonary arteriovenous fistulas and arterial distribution of eggs of Schistosoma mansoni. Am J trop Med Hyg 5:860–862, 1956Google Scholar
  10. 10.
    Lebrec D, Nouel O, Corbic M, Benhamou JP: Propranolol. A medical treatment for portal hypertension? Lancet 2:180–182, 1980Google Scholar
  11. 11.
    Lebrec D: β-Blockers and portal hypertension, hemodynamic effects and prevention of recurrent gastrointestinal bleeding. Hepatogastroenterology 37:556–560, 1990Google Scholar
  12. 12.
    Garcia-Tsao G, Grace ND, Groszmann RJ, Conn HO, Bermann MM, Patrick MJC, Morse SS, Alberts JL: Shortterm effects of propranolol on portal venous pressure. Hepatology 6:101–106, 1986Google Scholar
  13. 13.
    Rector WG Jr: Propranolol for portal hypertension. Evaluation of therapeutic response by direct measurement of portal veins pressure. Arch Intern Med 145:648–650, 1985Google Scholar
  14. 14.
    Vorobioff J, Picabea E, Villavicencio R, Puccini V, Rossi O, Bordato J, Audano M: Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patients. Hepatology 7:648–653, 1987Google Scholar
  15. 15.
    Bosch J, Garcia-Pagán JC, Feu F, Luca A, Fernandez M, Pizcueta P, Rodes J: New approaches in the pharmacological treatment of portal hypertension. J Hepatol 17:841–845, 1993Google Scholar
  16. 16.
    Pagliaro L, D'Amico G, Tine F, Pasta L: Prevention of upper gastrointestinal bleeding from portal hypertension in cirrhosis: rationale for medical treatment. Dig Dis 10:56–64, 1992Google Scholar
  17. 17.
    Acharya SK, Dasarathy S, Saksema S, Pande JH: A prospective randomized study to evaluate propranolol in patients undergoing long-term endoscopic sclerotherapy. J Hepatol 19:291–300, 1993Google Scholar
  18. 18.
    Avgerinos A, Rekoumis G, Klonis C, Papadimitriou N, Gouma P, Pournaras S, Raptis S: Propranolol in the prevention of recurrent upper gastrointestinal bleeding in patients with cirrhosis undergoing endoscopic sclerotherapy. A randomized controlled trial. J Hepatol 19:301–311, 1993Google Scholar
  19. 19.
    Mies S, Pereira MB, Orlando CD, Sette M, Raia S: Propranolol na preven{ie759-3} da recidiva de hemorragia digestiva em pacientes com esquistossomose hepatesplènica. Rev Assoc Med Bras 34:24–28, 1988Google Scholar
  20. 20.
    Coelho JL: Propranolol em portadores de hipertensão portal esquistossomótica (estudos hemodinâmicos). Thesis. Faculdade de Medicina, Universidade de São Paulo, São Paulo, 1987Google Scholar
  21. 21.
    Rao PS, Quesada LC, Mueller HS: A simple micromethod for simultaneous determination of plasma propranolol and 4-hydroxypropranolol. Clin Chim Acta 88:355–361, 1978Google Scholar
  22. 22.
    Baselt RC (ed): Propranolol. In Analytical Procedures for Therapeutic Drug Monitoring and Emergency Toxicology. Davis, Biomedical, 1980, pp 248–252Google Scholar
  23. 23.
    Lunderquist A, Vang J: Transhepatic catheterization and obliteration of the coronary vein in patients with portal hypertension and esophageal varices. N Engl J Med 291:646–649, 1974Google Scholar
  24. 24.
    Bosch J, Feu F, Garcia-Pagan JC: Measurement of azygos blood flow. In Portal Hypertension. Clinical and Physiological Aspects. K Okuda, J-P Benhamou (eds). Tokyo, Spring-Verlag, 1991, pp 139–150Google Scholar
  25. 25.
    Bosch J, Groszmann RJ: Measurement of azygos venous blood flow by a continuous thermal dilution technique: An index of blood flow through gastroesophageal collaterals in cirrhosis. Hepatology 4:424–429, 1984Google Scholar
  26. 26.
    Villeneuve JP, Huot R, Marleau D, Huet PM: The estimation of hepatic blood flow with indocyanine green: Comparison between the continuous infusion and single injection methods. Am J Gastroenterol 77:233–237, 1982Google Scholar
  27. 27.
    Barash PG, Kopriva CJ: Cardiac pump function and how to monitor it. In Manual of Cardiac Anesthesia. SJ Thomas (ed). New York, Churchill Livingstone, 1984, pp 1–34Google Scholar
  28. 28.
    Shoemaker WC: Monitoring of the critically ill patient. In Textbook of Critical Care. WC Shoemaker, WL Thompson, PR Holbrook (eds). Philadelphia, Saunders, 1984, pp 105–121Google Scholar
  29. 29.
    Ohnishi K, Chin N, Tanaka H, Iida S, Sato S, Terabayashi H, Nomura F: Differences in portal hemodynamics in cirrhosis and idiopathic portal hypertension. Am J Gastroenterol 84:409–412, 1989Google Scholar
  30. 30.
    Lautt WW, Greenway CV: Conceptual review of the hepatic vascular bed. Hepatology 7:952–963, 1987Google Scholar
  31. 31.
    Coutinho A: Hemodynamic studies of portal hypertension in schistosomiasis. Am J Med 44:547–556, 1968Google Scholar
  32. 32.
    Carneiro JLA: A circula{ie760-1} colateral gastresofágica após desconexão ázigo-portal. Portografia trans-hepática na esquistossomose mansônica. Thesis. Centro Biomédico Universidade Federal do Espírito Santo, Vitória, 1979Google Scholar
  33. 33.
    Shand DG: Individualization of propranolol therapy. Med Clin North Am 58:1063–1069, 1974Google Scholar
  34. 34.
    Lindenfeld J, Crawford MH, O'Rourke RA, Levine SP, Montiel MM, Hosrwitz LD: Adrenergic responsiveness after abrupt propranolol withdrawal in normal subjects and in patients with angina pectoris. Circulation 62:704–711, 1980Google Scholar
  35. 35.
    Biber B, Holm C, Winsö O, Gustavsson B: Portal blood flow in man during surgery, measured by a modification of the continuous thermodilution method. Scand J Gastroenterol 18:233–239, 1983Google Scholar
  36. 36.
    Fomon JJ, Warren WD: Hemodynamic studies in portal hypertension. Annu Rev 20:277–290, 1969Google Scholar
  37. 37.
    Bosch J, Ginés P, Arroyo V, Navasa M, Rodes J: Hepatic and systemic hemodynamics and the neurohumoral systems in cirrhosis. In The Kidney in Liver Disease, 3rd ed. M Epstein (ed). Baltimore, Williams & Wilkins, 1988, pp 286–305Google Scholar
  38. 38.
    Lebrec D: Hepatic vein catheterization. In Portal Hypertension. Clinical and Phisiological Aspects. K Okuda, J-P Benhamou (eds). Tokyo, Springer-Verlag, 1991, pp 117–125Google Scholar
  39. 39.
    Lautt WW, Greenway CV: Hepatic circulation in homeostasis. In The Kidney in Liver Disease, 3rd ed. M Epstein (ed). Baltimore, Williams & Wilkins, 1988, pp 244–261Google Scholar
  40. 40.
    Jenkins WJ, Billing B: Physiology of the liver. In Bockus Gastroenterology, Vol 5, 4th ed. JE Berk (ed). Philadelphia, Saunders, 1985, pp 2666–2696Google Scholar
  41. 41.
    Meyers WC: Anatomy and physiology. In Textbook of Surgery. The Biological Basis of Modern Surgical Practice, 13th ed. DC Sabiston Jr (ed). Philadelphia, Saunders, 1986, pp 1053–1068Google Scholar
  42. 42.
    Henderson JM, Warren WD: Surgical complications of cirrhosis and portal hypertension. In Textbook of Surgery. The Biological Basis of Modern Surgical Practice, 13th ed. DC Sabiston Jr (ed). Philadelphia, Saunders, 1986, pp 1095–1116Google Scholar
  43. 43.
    Mahl TC, Groszmann RJ: The pathophysiology of portal hypertension. In Portal Hypertension. Clinical and Physiological Aspects. K Okuda, J-P Benhamou (eds). Tokyo, Springer-Verlag, 1991, pp 27–33Google Scholar
  44. 44.
    Bradley SE, Ingelfinger FJ, Bradley GP, Curry JJ: The estimation of hepatic blood flow in man. J Clin Invest 24:890–897, 1945Google Scholar
  45. 45.
    Leevy CM, Mendenhall CL, Lesko W, Howard MM: Estimation of hepatic blood flow with indocyanine green. J Clin Invest 41:1169–1180, 1962Google Scholar
  46. 46.
    Rowell LB, Blackmon JR, Bruce RA: Indocyanine green clearance and estimated hepatic blood flow during mild to maximal exercise in upright man. J Clin Invest 43:1677–1690, 1964Google Scholar
  47. 47.
    Frishman WH: Pharmacodynamic and pharmacokinetic properties. In Clinical Pharmacology of the Beta-Adrenoceptor Blocking Drugs. WH Frishamn (ed). New York, Appleton, 1980, pp 1–14Google Scholar
  48. 48.
    MacMathuna P, Viavianos P, Wendon J, Gove CD, Westaby D, Williams R: Metabolic effects of β-receptor blockade in advanced alcoholic cirrhosis. J Hepatol 17:74–80, 1993Google Scholar
  49. 49.
    Bendtsen F, Christense NJ, Sörensen TIA, Henriksen JH: Effect of oral propranolol administration on azygos, renal and hepatic uptake and output of catecholamines in cirrhosis. Hepatology 14:237–243, 1991Google Scholar
  50. 50.
    Braillon A, Calès P, Valla D, Gaudy D, Geoffroy P, Lebrec D: Influence of the degree of liver failure on systemic and splanchnic haemodynamics and on response to propranolol in patients with cirrhosis. Gut 27:1204–1209, 1986Google Scholar
  51. 51.
    Schrier RW, Caramelo C: Hemodynamics and hormonal alterations in hepatic cirrhosis. In The Kidney in Liver Disease. M Epstein (ed). Baltimore, Williams & Wilkins, 1988, pp 265–285Google Scholar
  52. 52.
    Bonizon A, Blendis LM: The nitric oxide hypothesis and the hyperdynamic circulation in cirrhosis. Hepatology 20:1343–1350, 1994Google Scholar
  53. 53.
    Shelmann WH: Hyperdinamic circulation in cirrhosis: A historical perspective. Hepatology 20:1356–1358, 1994Google Scholar
  54. 54.
    MacDougall BRD, Westaby D, Blendis LA: Portal hypertension—25 years of progress. Gut Suppl:S18–S24, 1991Google Scholar
  55. 55.
    Bina JC, Prata A: A evolu{ie760-2} natural da esquistossomose mansoni em um área endèmica. In Aspectos peculiares da infec{ie760-3} por Schistosoma mansoni. ES Azevedo, G Rebouças, H Rocha, LGC Lyra, RS Teixeira, S Andrade, ZA Andrade (eds). Salvador, Centro Editorial e Didático da UFBA, 1984, pp 13–33Google Scholar
  56. 56.
    Andrade ZA, Andrade SG: Patologia da esquistossomose hepatoesplènica. In Aspectos peculiares da infec{ie760-4} por Schistosoma mansoni. ES Azevedo, G Rebouças, H Rocha, LGC Lyra, RS Teixeira, S Andrade, ZA Andrade (eds). Salvador, Centro Editorial e Didático da UFBA, 1984, pp 103–131Google Scholar
  57. 57.
    Rivero MA, Marcial MA, Reyes A: Pathology of pulmonary hypertension on Schistosomiasis mansoni. PR Health Sci J 12:43–45, 1993Google Scholar
  58. 58.
    Lopes de Faria J, Barbas JV, Fujioka T, Lion MF, Silva UA, Decourt LV: Pulmonary schistosomatic arteriovenous fistulas producing a new cyanotic syndrome in Manson's schistosomiasis. Am Heart J 58:556–567, 1959Google Scholar
  59. 59.
    Hadengue A, Lebrec D, Benhamou J-P: Pulmonary arterial hypertension in patients with portal hypertension. In Portal Hypertension. Clinical and Physiological Aspects. K Okuda, J-P Benhamou (eds). Tokyo, Springer-Verlag, 1991, pp 401–411Google Scholar
  60. 60.
    Rakela J, Krowka MJ: Cardiovascular and pulmonary complications of liver diseases. In Hepatology. A Textbook of Liver Disease, Vol. 1, 2nd ed. D Zakim, TD Boyer (eds). Philadelphia, Saunders, 1990, pp 530–537Google Scholar
  61. 61.
    Weiner N: Drugs that inhibit adrenergic nerves and block adrenergic receptors. In The Goodman and Gilman's Pharmacological Basis of Therapeutics, 7th ed. AG Gilman, LS Goodman, TW Rall, F Murad (eds). New York, Macmillan, 1985, pp 181–214Google Scholar
  62. 62.
    Bosch J, Mastai R, Kravetz D, Bruix J, Rigau J, Rodes J: Measurement of azygos venous blood flow in the evaluation of portal hypertension in patients with cirrhosis. Clinical and haemodynamic correlations in 100 patients. J Hepatol 1:125–139, 1985Google Scholar
  63. 63.
    Calès P, Braillon A, Jirón MI, Lebrec D: Superior portosystemic collateral circulation estimated by azygos blood flow in patients with cirrhosis. Lack of correlation with oesophageal varices and gastrointestinal bleeding. Effect of propranolol. J Hepatol 1:37–46, 1984Google Scholar
  64. 64.
    Kashiwagi T, Kamada T, Abe H: Dynamic studies on the portal hemodynamics by scintiphotosplenoportography. Streamline flow in the human portal vein. Gastroenterology 69:1292–1296, 1975Google Scholar
  65. 65.
    Fausto N: Hepatic regeneration. In Hepatology. A Textbook of Liver Disease, Vol 1, 2nd ed. D Zakim, TD Boyer (eds). Philadelphia, Saunders, 1990, pp 49–65Google Scholar
  66. 66.
    Zoller WG, Wagner DR, Zentner J: Effect of propranolol on portal vein hemodynamics in patients with liver cirrhosis: Assessment by duplex sonography. Z Gastroenterol 31:425–428, 1993Google Scholar
  67. 67.
    Feu F, Bordas JM, Luca A, Garcia-Pagan JC, Escorsell A, Bosch J, Rodés J: Reduction of variceal pressure by propranolol: Comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis. Hepatology 18:1082–1089, 1993Google Scholar
  68. 68.
    Raia S, da Silva LC, Gayotto LCC, Forster SC, Fukushima J, Strauss E: Portal hypertension in schistosomiasis. A long-term follow-up of a randomized trial comparing three types of surgery. Hepatology 20:398–403, 1994Google Scholar

Copyright information

© Plenum Publishing Corporation 1997

Authors and Affiliations

  • Sergio Mies
  • Oddone Braghirolli Neto
  • Andre Beer
  • Carlos E.S. Baia
  • Fernando Alfieri
  • Leila M.M.B. Pereira
  • Marcelo J.A. Sette
  • Silvano Raia

There are no affiliations available

Personalised recommendations